LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Ardavani, Ashkon"
  2. AU="Huijeong Ahn"

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: The effect of pharmacist-led interventions on the management and outcomes in chronic kidney disease (CKD): A systematic review and meta-analysis protocol.

    Ardavani, Ashkon / Curtis, Ffion / Khunti, Kamlesh / Wilkinson, Thomas J

    Health science reports

    2023  Volume 6, Issue 1, Page(s) e1064

    Abstract: Background and aims: Chronic kidney disease (CKD) is a progressive condition that results in a decline in kidney function over time. There are several conditions that increase the likelihood of developing CKD, particularly diabetes and hypertension. CKD ...

    Abstract Background and aims: Chronic kidney disease (CKD) is a progressive condition that results in a decline in kidney function over time. There are several conditions that increase the likelihood of developing CKD, particularly diabetes and hypertension. CKD increases the risk of mortality and has a detrimental impact on quality of life (QoL). Strategies for managing CKD include controlling cardiovascular risk factors and treating complications of CKD. There is an ever-increasing role of pharmacists in managing CKD, from the optimization of risk factors to patient education. However, currently, there is a lack of data on the effect pharmacist-led interventions have on the clinical, economic, and humanistic outcomes.
    Methods: This protocol, in adherence to PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) standards, describes a prospective systematic review and meta-analysis of randomized controlled trials, where any intervention led by a pharmacist in CKD is used. Comparison groups will consist of usual care or non-pharmacist-led interventions. Literature searches will be conducted in the following databases: MEDLINE, Scopus, and Web of Science. Data pertaining to clinical (e.g., mortality), economic (e.g., healthcare-associated costs), and humanistic (e.g., QoL) outcomes will be extracted. Risk of bias will be assessed using the United States National Heart Lung and Blood Institute quality assessment tool for controlled intervention studies. A meta-analysis will be conducted to synthesize appropriate comparable outcomes.
    Results: The findings of this review will be published in a peer-reviewed journal, where the results will be presented in lay language with appropriate infographics online and via social media.
    Conclusion: The findings of this review can identify gaps in the literature concerning optimizing pharmacist-led interventions in improving outcomes. In addition, this review will establish the importance of pharmacists in managing CKD patients, and whether this may result in their increased incorporation in multidisciplinary teams.
    Language English
    Publishing date 2023-01-14
    Publishing country United States
    Document type Journal Article
    ISSN 2398-8835
    ISSN (online) 2398-8835
    DOI 10.1002/hsr2.1064
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Corrigendum to "The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis".

    O'Mahoney, Lauren L / Routen, Ash / Gillies, Clare / Ekezie, Winifred / Welford, Anneka / Zhang, Alexa / Karamchandani, Urvi / Simms-Williams, Nikita / Cassambai, Shabana / Ardavani, Ashkon / Wilkinson, Thomas J / Hawthorne, Grace / Curtis, Ffion / Kingsnorth, Andrew P / Almaqhawi, Abdullah / Ward, Thomas / Ayoubkhani, Daniel / Banerjee, Amitava / Calvert, Melanie /
    Shafran, Roz / Stephenson, Terence / Sterne, Jonathan / Ward, Helen / Evans, Rachael A / Zaccardi, Francesco / Wright, Shaney / Khunti, Kamlesh

    EClinicalMedicine

    2023  Volume 59, Page(s) 101959

    Abstract: This corrects the article DOI: 10.1016/j.eclinm.2022.101762.]. ...

    Abstract [This corrects the article DOI: 10.1016/j.eclinm.2022.101762.].
    Language English
    Publishing date 2023-04-19
    Publishing country England
    Document type Published Erratum
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.101959
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis.

    O'Mahoney, Lauren L / Routen, Ash / Gillies, Clare / Ekezie, Winifred / Welford, Anneka / Zhang, Alexa / Karamchandani, Urvi / Simms-Williams, Nikita / Cassambai, Shabana / Ardavani, Ashkon / Wilkinson, Thomas J / Hawthorne, Grace / Curtis, Ffion / Kingsnorth, Andrew P / Almaqhawi, Abdullah / Ward, Thomas / Ayoubkhani, Daniel / Banerjee, Amitava / Calvert, Melanie /
    Shafran, Roz / Stephenson, Terence / Sterne, Jonathan / Ward, Helen / Evans, Rachael A / Zaccardi, Francesco / Wright, Shaney / Khunti, Kamlesh

    EClinicalMedicine

    2022  Volume 55, Page(s) 101762

    Abstract: Background: The aim of this study was to systematically synthesise the global evidence on the prevalence of persistent symptoms in a general post COVID-19 population.: Methods: A systematic literature search was conducted using multiple electronic ... ...

    Abstract Background: The aim of this study was to systematically synthesise the global evidence on the prevalence of persistent symptoms in a general post COVID-19 population.
    Methods: A systematic literature search was conducted using multiple electronic databases (MEDLINE and The Cochrane Library, Scopus, CINAHL, and medRxiv) until January 2022. Studies with at least 100 people with confirmed or self-reported COVID-19 symptoms at ≥28 days following infection onset were included. Patient-reported outcome measures and clinical investigations were both assessed. Results were analysed descriptively, and meta-analyses were conducted to derive prevalence estimates. This study was pre-registered (PROSPERO-ID: CRD42021238247).
    Findings: 194 studies totalling 735,006 participants were included, with five studies conducted in those <18 years of age. Most studies were conducted in Europe (n = 106) or Asia (n = 49), and the time to follow-up ranged from ≥28 days to 387 days. 122 studies reported data on hospitalised patients, 18 on non-hospitalised, and 54 on hospitalised and non-hospitalised combined (mixed). On average, at least 45% of COVID-19 survivors, regardless of hospitalisation status, went on to experience at least one unresolved symptom (mean follow-up 126 days). Fatigue was frequently reported across hospitalised (28.4%; 95% CI 24.7%-32.5%), non-hospitalised (34.8%; 95% CI 17.6%-57.2%), and mixed (25.2%; 95% CI 17.7%-34.6%) cohorts. Amongst the hospitalised cohort, abnormal CT patterns/x-rays were frequently reported (45.3%; 95% CI 35.3%-55.7%), alongside ground glass opacification (41.1%; 95% CI 25.7%-58.5%), and impaired diffusion capacity for carbon monoxide (31.7%; 95% CI 25.8%-3.2%).
    Interpretation: Our work shows that 45% of COVID-19 survivors, regardless of hospitalisation status, were experiencing a range of unresolved symptoms at ∼ 4 months. Current understanding is limited by heterogeneous study design, follow-up durations, and measurement methods. Definition of subtypes of Long Covid is unclear, subsequently hampering effective treatment/management strategies.
    Funding: No funding.
    Language English
    Publishing date 2022-12-01
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2022.101762
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top